Type One Diabetes Completed Phase Trials for Insulin degludec (DB09564)

Back to Type One Diabetes

Also known as: Diabetes Mellitus, Juvenile-Onset / T1DM - Type 1 Diabetes Mellitus / Diabetes Type I / Type I Diabetes / Type1 Diabetes / Diabetes Type One / Diabete Type 1 / Type One Diabetes Mellitus / Diabetics Mellitus Type 1 / Type 1 Diabetes / Type 1 Diabetes Mellitus (T1DM) / Insulin-Dependent Diabetes Mellitus 1 / Type1diabetes / Diabetes Mellitus Type I / Type1 Diabetes Mellitus / Type 1 Diabetes (T1D) / Diabetes Mellitus Type 1 / Juvenile Onset Diabetes Mellitus / Diabetes Type 1 / Type 1 Insulin-Dependent Diabetes Mellitus / Type I Diabetes Mellitus / Diabetes Mellitus, Sudden-Onset / Type-1 Diabetes Mellitus / Insulin Dependent Diabetes Mellitus 1 / Type 1 Diabetes Mellitus / Juvenile-Onset Diabetes / Diabetes Mellitus, Insulin-Dependent, 1 / Diabetes mellitus type 1 (disorder) / Diabetes mellitus: [juvenile] or [insulin dependent] / Juvenile diabetes / Insulin dependent diabetic / IDDM / Diabetes mellitus insulin-dependent / Insulin-dependent diabetes mellitus / Diabetes mellitus juvenile onset / Immune-mediated diabetes / Insulin dependent diabetes mellitus / Insulin dependent diabetes mel / IDDM - Insulin-dependent diabetes mellitus / Diabetes mellitus - juvenile / Ketosis-prone diabetes mellitus (disorder) / Ketosis-prone diabetes mellitus

Indication	Status	Phase
DBCOND0076728 (Type One Diabetes)	Completed	Not Available

clinicaltrials.gov Identifier	Title	Drugs
NCT05434559	Evaluation of Glycemic Control in Adults With Type 1 Diabetes When Switching to Insulin Degludec	Insulin degludec (DB09564)
NCT05069545	A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice	Insulin aspart (DB01306) Insulin degludec (DB09564)
NCT02360254	Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes	Insulin degludec (DB09564)
NCT01984372	Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®	Insulin degludec (DB09564)
NCT03416855	A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea	Insulin aspart (DB01306) Insulin degludec (DB09564)
NCT02230618	Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India	Insulin aspart (DB01306) Insulin degludec (DB09564)
NCT02392117	Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus	Insulin degludec (DB09564)
NCT02117622	A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India	Insulin degludec (DB09564) Insulin human (DB00030)
NCT03674866	A Canadian Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus	Insulin degludec (DB09564)